New Zealand standardised oral formulation batch sheet

Omeprazole suspension 2 mg/mL (100 mL)

Patient's name		**Storage condition**	**In a refrigerator**	**At room temperature**
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	15 days	Not recommended
Batch number		Recommended storage	☑	-

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Omeprazole powder/capsules				200 mg			
Sodium bicarbonate powder				8.4 g			
Water§				to 100 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted?	Not applicable
Calculations performed by	
Calculations checked by (pharmacist)	
Area cleared for processing by	

Instructions to compound suspension:

1. Prepare the sodium bicarbonate 8.4% solution.
2. To quicken dissolution of the sodium bicarbonate powder, warm water may be used.
3. Dissolve omeprazole powder / capsule pellets in the sodium bicarbonate solution.
4. Make up to the final volume and mix well.
5. Label and package product appropriately.

Labels

Attach product label and auxiliary labels:	Label checked by

Omeprazole suspension 2 mg/mL (100 mL)

Final yield	_____ mL	Checked by	
Final appearance of product	Milky white suspension.		
Container	Amber plastic mission bottle.		
Compounded by	*Name:*	*Signature:*	*Date:*
Final check and product release	*Name:*	*Signature:*	*Date:*

Special instructions:

1. Consider using a commercially available product.
2. § Water used for compounding must be compliant with the Health and Disability Services Pharmacy Services Standard (NZS 8134.7.2010; Standards New Zealand, 2010), standard 5.19 *Starting materials shall be of a quality suitable for use in products intended for therapeutic use*. Potable water includes filtered tap water, water for irrigation or water for injection.
3. Shake well before use.
4. Store in a refrigerator. Do not freeze. Refrigerator storage is recommended as data available for room temperature storage are conflicting depending on the compounding method used.
5. Do not use if the colour of the suspension darkens.
6. Do not use if sedimentation occurs.

References:

1. Anonymous. *Int J Pharm Compd*, 2006; **10**(5): 389.
2. Garg S, Svirskis D, Al-Kabban M, et al. *Int J Pharm Compd*, 2009; **13**(3): 250-3.
3. Makeen H, Pancholi S, Ali M, et al. *Saudi J Health Sci*, 2018; **7**(1): 28-32.
4. Quercia RA, Fan C, Liu X, et al. *Am J Health Syst Pharm*, 1997; **54**(16): 1833-6.

Prepared by	New Zealand Compounding Working Group		
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	4.0	Version approval date	15/08/19
Document review due	01/09/21		